Navigation Links
EP Global Communications, Inc. Achieves Shareholder Approval for Restructuring and Signs Definitive Restructuring Agreement
Date:6/27/2012

Johnstown, PA (PRWEB) June 27, 2012

EP Global Communications, Inc. (the Company) , (Pink Sheets: EPGL.PK), is pleased to announce that on June 8, 2012 , shareholders approved the proposed 10:1 reverse split and restructuring plan. Accordingly, as of June 21, 2012 the Company has entered a Definitive Restructuring Agreement with the major corporate parties and restructuring partners including the Company, the joint liquidators of the various AJW Funds from PwC Corporate Finance and Recovery (Caymans) Limited and Digital Health Sciences, Inc. a U.S. medical device company.

The Company has set an approximate date of July 8, 2012 for the “effective date” of the 10:1 reverse split. Upon the reverse split, the outstanding shares of EPGL common stock will be reduced to approximately 499 million shares outstanding. Shareholders should expect the ask price for Company common stock, to increase mathematically by ten times the last asking price prior to the reverse split, as a result. Share price will fluctuate from that point based on market conditions and investor interest.

As per the Definitive Restructuring Agreement the Company has now converted 100% of its major debt holders to that of equity holders in the newly restructured Company, extinguishing nearly $10 million dollars of debt. Also, upon the reverse split, the Company will close on the acquisition of Digital Health Sciences, Inc., a U.S. medical device company holding license to all rights, title and interest in SPOC, LLC., maker of the Muscle Pain Detection Device or MPDD which is an extremely promising new medical device, researched and developed by leading scientists at New York University and has not been marketed to physicians anywhere in the world, as yet. As a result of this transaction, SPOC, LLC will be wound up and dissolved. The assets of SPOC, LLC include but are not limited to, the MPDD device itself, device designs, existing devices, and FDA 510k clearance for marketing and manufacturing of the device. The Company plans for this device to be the first of several medical devices it will market in the future.

Joseph M. Valenzano Jr. has resigned from the company along with all previous management and Directors as of June 22, 2012. Prior to departure, previous management approved the changing of the Corporate Charter to that of Medical Device Manufacturer. The restructuring partners are currently in talks with new management candidates and have chosen a new Company Medical Director who’s name will be announced in the near future via press release. Additionally, a new company website will be revealed in the near future.

The restructuring partners look forward to bringing significant value back to the Company and its shareholders. More public announcements will be forthcoming in the near future regarding exact date for the reverse split, new management and new financial disclosures.
About EP Global Communications, Inc.

EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
________________________________________
Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances

Read the full story at http://www.prweb.com/releases/2012/6/prweb9644770.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Canada should play a role in addressing the global cancer epidemic
3. Global cardiology leaders meet in Dubai
4. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
5. International breast health global summit will focus on supportive care and quality of life
6. Scientists rewrite rulebook on breast cancer in landmark global study
7. Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology
8. Centre for Global Non-Communicable Diseases launched to tackle killer diseases
9. UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity
10. New study identifies how information technology is used to solve global health challenges
11. New global report says US lags behind 130 other nations in preterm birth rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... ... , ... There is no doubt in anyone’s mind that NoSQL databases scale out to large ... the ability to scale to a 1000 nodes, Gensonix can scale to 100,000 nodes without ... Big Data loads. , First of all, Gensonix stands as the only DB (SQL or ...
(Date:8/24/2017)... Fredericton, NB (PRWEB) , ... August 24, 2017 , ... ... culmination of 18 years of contact center application development experience. It represents ... modern contact center. , Indosoft designed Q-Suite NG for simple integration. A full ...
(Date:8/23/2017)... , ... August 23, 2017 , ... The Arc Mercer, ... disabilities (I/DD), has launched a groundbreaking LGBTQ community organization for people with special needs. ... organization of its kind in the state of New Jersey – but the first ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... Vice President Business Development and Sector Growth. Mr. Smith joins other recent high-profile ... , Mr. Smith’s healthcare career began in 1993, helping physician practices and ...
(Date:8/23/2017)... ... August 23, 2017 , ... Based on worldwide research and ... of HBOT in treating and helping to heal addictions and substance abuse disorders. ... similarities of the wounds to the brain from traumatic brain injuries, and the ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology: